For example, a drug that represents a genuine medical breakthrough could be rewarded with a prolonged period of market exclusivity, while a replica drug or a modification that merely offers greater convenience, such as a once-a-day formulation, could be granted shorter periods. Drugs judged to offer no significant benefit to patients (a chewable birth control pill?) could receive no market protection at all.
